XELOSTAD 10 Stella to prevent venous thrombosis (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Rivaroxaban

Ingredient

Composition information	Content
Rivaroxaban	10mg

Uses

indications

XELOSTAD indications for treatment in the following cases:

Prevention of venous thromboembolism (VTE) in adults has surgery under the hip or knee replacement program.

Dynamic pharmacokinetics

There is no reported data.

Before taking XELOSTAD 10 Stella to prevent venous thrombosis (3 blisters x 10 tablets)

How to use

xeLostad 10mg Film tablets are used by oral, drink with or not with food.

For patients who cannot swallow whole, XeLostad 10mg can be ground mixed with water, soft food like apple juice right before use and used by oral.

The tablet of tablets 10mg can be taken through the gastric catheter, after determining the exact pipe setting the stomach position. The crushed pills are mixed into a small amount of water into the catheter, then add a little water to coat the tube.

Dosage

adults

The usual dose in the prevention of venous thrombosis (VTE):

Patients with dose: 10mg Rivaroxaban, 1 time/day, should be used within 6 - 10 hours after surgery, with controlled hemostasis. Relapse DVT and PE:

Patients with treatment dose:

Start 15 mg, 2 times/day for the first 3 weeks, continue treatment and prevent recurrence: 20 mg x 1 time/day. Historical relapse DVT/PE. In patients with high risk of recurrence, consider the dose of 20 mg x 1 time/day. Carefully evaluate the benefits of treatment compared to the risk of bleeding.

Common dosage in case of indications for conversion from XELostad 10mg to vitamin K antagonists (VKA):

Patients need to ensure adequate and continuous anticoagulants during the transition to anticoagulants instead, it should be noted that XeLostad 10 can contribute to the increase in the Inr value.

Patients should use VKA simultaneously until INR ≥ 2.0.

In the first two days, the manufacturer recommends that the standard VKA dose should be used, followed by the VKA dose based on Inr test. In the case of patients using both xeLostad 10mg and VKA, the Inr should not be tested before 24 hours after the previous dose or before taking the next dose of XeLostad 10mg. Once XeLostad 10mg is interrupted, the Inr test can be conducted with a reliable level of 24 hours after the last dose.

Common dosage in case of indications for conversion from anticoagulant drugs to XeLostad 10mg:

Stop using anticoagulants and start xeLostad 10mg from 0-2 hours before the next time of injection (for example, heparin has a low molecular weight) or at the time of the stop of a continuous injection drug (eg non -segmented heparin intravenous injection).

Common dosage in case of indications for conversion from xeLostad 10mg to injection anticoagulant drugs:

Inject anticoagulant first dose at the time of the next dose of xeLostad 10mg.

Children

Do not use drugs for children under 18 years old.

Special subjects

Patients with renal failure:

It is recommended not to be used in patients with creatinine clearance

Patients with liver failure:

Contraindicated XELostad 10mg in patients with liver disease associated with blood clotting and the risk of clinical bleeding including clinical cirrhosis patients with Pugh B and C.

No need to adjust the dose by weight, gender.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when using overdose?

What to do when forgetting 1 dose? Usually. Do not use twice the same dose in the same day to compensate for the forgotten dose.

Side Effects

When using XELostad 10mg, you may experience unwanted effects (ADR).

Common (1/100 ≤ ADR

Common side effects include:

Anemia (including corresponding test parameters).

Dizziness, headache. vomiting. Transaminase.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

XELOSTAD 10mg drug contraindicated in the following cases:

Patients with hypersensitivity to the ingredients of the drug. This may include or recently suffering from gastrointestinal ulcer, a malignant tumor with a high risk of bleeding, recently brain or spine damage, recently surgery for brain, spine or eye, recent intracranial hemorrhage, know or suspect esophageal varicose veins, venous deformities, aortic aneurysms, large blood vessels in the spine or intracranized drugs. Especially in the anticoagulant conversion process or when heparin is not segmented (UFH) is used at the dose necessary to maintain the open catheter or open central vein.

Caution when using

should be very cautious when taking the drug for patients in the following cases:

Patients may have hemorrhage risk:

Precautions used for cases of high risk of bleeding (congenital bleeding disorders or suffering from uncontrolled serious arterial hypertension; other gastrointestinal ulcers without progressive ulcers can lead to complications of bleeding; Retinal disease due to blood vessels; bronchodilator or history of pulmonary bleeding).

Need to stop using xeLostad 10mg when there is serious bleeding.

Patients with renal failure:

Use carefully xeLostad 10mg for patients with renal impairment with creatinine clearance 15 - 29 ml/min. Do not use for patients with creatinine clearance In case of spinal anesthesia/ epidural or spinal cord detection for patients:

It is necessary to consider the benefits and risks before interfering with the cerebrospinal axis in patients with anticoagulants or anticoagulants to prevent thrombosis. Regular monitoring of signs and symptoms of neurological decline (such as numb or weak legs, colon or bladder dysfunction). If there is a neurological decline, it is necessary to diagnose and treat it promptly. After withdrawing the catheter, at least 6 hours later used Rivaroxaban to follow the next dose. If the damage is damaged, it is necessary to delay the use of Rivaroxaban up to 24 hours.

recommended dose before and after invasive procedures, surgical interventions other than tricks to replace hip and knee joints:

If surgery or invasive procedure should be stopped, should stop taking XELostad 10mg before surgery for at least 24 hours, if possible or based on the clinical assessment of the doctor. Clinically allowed and when hemostasis is set under the decision of the treating doctor.

Be cautious when using drugs in the elderly: The risk of bleeding may increase with age.

There may be skin reactions: Rivaroxaban should be discontinued if serious skin rashes appear (spreading, red swelling or blistering) or any hypersensitivity reaction with mucosal damage.

XELostad 10mg contains Lactose excipients. This drug should not be used for patients with rare genetic problems galactose intolerance, total lactase enzyme deficiency or poorly absorbed glucose-galactose.

Use drugs for pregnant and lactating women

Contraindicated use of XELOSTAD 10mg for pregnant and nursing pregnant women.

The effect of the drug on the ability to drive and operate machinery

Need to pay attention to the body's response to the drug before driving operating machinery.

Drug interaction

drug interactions may affect the activity of the drug or cause side effects. Should notify the doctor or pharmacist a list of drugs and functional foods you are using. Do not use or increase or decrease the dose of the drug without the guidance of a doctor.

Do not use xeLostad 10mg for patients who are using antifungal drugs Azole in the body or HIV protease inhibitors.

Be cautious for patients treated simultaneously with drugs that affect red blood cells such as nonsteroidal anti -inflammatory drugs (NSAID), acetylsalicylic acid (ASA), platelet anti -platelets, selective Serotonin reabsorption (SSRIs) and Serotonin - norepinephrine (SNRRine).

Safety and effectiveness of XELOSTAD 10mg has not been set in patients with artificial cardiac valves. Therefore, do not use HELostad 10mg for this group of patients.

Rivaroxaban has not been studied in clinical trials interventions in patients with hip fracture surgery to evaluate safety and effectiveness.

Storage

Leave a cool place, avoid light, temperature below 30⁰C.

To be out of reach of children.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.